IN THE CLAIMS

Claims 1-27 (Canceled).

28. (Previously Presented) A method for inducing cell death comprising exposing a cell which overexpresses ErbB2 to an effective amount of an isolated antibody that binds to an epitope on ErbB2 to which antibody 7C2 binds.

29. (Original) The method of Claim 28 wherein the cell is a cancer cell.

30. (Original) The method of Claim 28 wherein the cell is in a mammal.

31. (Original) The method of Claim 30 wherein the mammal is a human.

32. (Previously Presented) The method of Claim 28 further comprising exposing a cell to a second anti-ErbB2 antibody which does not bind to an epitope on ErbB2 to which antibody 7C2 binds.

33. (Original) The method of Claim 28 further comprising exposing the cell to a second antibody which binds ErbB2 and inhibits growth of SKBR3 cells in cell culture by 50-100%.

34. (Previously Presented) The method of Claim 33 wherein the cell is exposed to the antibody that binds to an epitope on ErbB2 to which antibody 7C2 binds before the cell is exposed to the second antibody.

35. (Original) The method of Claim 33 wherein the second antibody binds to epitope 4D5 on ErbB2.

36. (Original) The method of Claim 35 wherein the second antibody has complementarity determining regions (CDRs) of antibody 4D5.

37. (Original) The method of Claim 28 further comprising exposing the cell to a growth inhibitory agent.

38. (Original) The method of Claim 28 further comprising exposing the cell to a chemotherapeutic agent.

39. (Original) The method of Claim 28 further comprising exposing the cell to radiation.

40. (Previously Presented) A method for inducing cell death comprising exposing a cell which overexpresses ErbB2 to an effective amount of an isolated antibody which binds to ErbB2 and results in about 5 to 50 fold induction of annexin binding relative to untreated cell in an annexin binding assay using BT474 cells.

41. Canceled

42. (Previously Presented) A method for inducing cell death comprising exposing a cell which overexpresses ErbB2 to an effective amount of a composition comprising an antibody that binds to an epitope on ErbB2 to which antibody 7C2 binds and a pharmaceutically acceptable carrier, wherein the antibody results in about 5 to 50 fold induction of annexin binding relative to untreated cell in an annexin binding assay using BT474 cells.

43. (Previously Presented) The method of Claim 42 wherein the cell is a cancer cell.

44. (Previously Presented) The method of Claim 42 wherein the cell is in a mammal.

45. (Previously Presented) The method of Claim 44 wherein the mammal is a human.

46. (Previously Presented) The method of Claim 28 wherein the antibody binds to epitope 7C2 on ErbB2.

47. (Previously Presented) The method of Claim 28 wherein the antibody induces death of a cell which overexpresses ErbB2.

48. (Previously Presented) The method of Claim 47 wherein the antibody induces cell death via apoptosis.

49. (Previously Presented) The method of Claim 28 wherein the antibody is a monoclonal antibody.

50. (Previously Presented) The method of Claim 28 wherein the antibody has nonhuman complementarity determining region (CDR) residues and human framework region (FR) residues.

51. (Previously Presented) The method of Claim 28 wherein the antibody is humanized 7C2.

52. (Previously Presented) The method of Claim 28 wherein the antibody is a human antibody.

53. (Previously Presented) The method of Claim 28 wherein the antibody has complementarity determining regions (CDRs) of antibody 7C2.

54. (Previously Presented) The method of Claim 28 wherein the antibody is an intact antibody.

55. (Previously Presented) The method of Claim 54 wherein the antibody comprises a human IgG heavy chain constant domain.

56. (Previously Presented) The method of Claim 28, wherein said isolated antibody has been purified to greater than 95% by weight as determined by Lowry method.

57. (Previously Presented) The method of Claim 56, wherein said isolated antibody has been purified to greater than 99% by weight as determined by Lowry method.

58. (Previously Presented) A method for inducing cell death comprising:

exposing a cell that overexpresses ErbB2 to a first antibody that binds to an epitope on ErbB2 to which antibody 7C2 binds; and

subsequently exposing the cell to a second antibody that binds to a domain of ErbB2 other than the binding site of antibody 7C2.

59. (Previously Presented) The method of Claim 42, wherein said antibody is selected from the group consisting of a chimeric antibody, a polyclonal antibody, a monoclonal antibody and a humanized antibody.

60. (Previously Presented) The method of Claim 42, wherein the antibody induces cell death via apoptosis.

61. (Previously Presented) The method of Claim 42, further comprising exposing the cell to a chemotherapeutic agent.

62. (Previously Presented) The method of Claim 42, further comprising exposing the cell to radiation.

63. (Previously Presented) A method for inducing cell death comprising exposing a cell which overexpresses ErbB2 to an effective amount of an isolated antibody that binds to an epitope on ErbB2;

wherein said isolated antibody induces cell death.

64. (Previously Presented) The method of Claim 63, wherein said second anti-ErbB2 antibody does not bind to an epitope on ErbB2 to which antibody 7C2 binds.